Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist…
Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC.
It has been approved in June 2026 for use in treating for solid tumors in China.
References
Gebaseerd op: Wikipedia — Eratrectinib · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.